GT DIAGNOSTICS

DEMENTIA DETECTION APPLICATIONS
& DIAGNOSTIC SOLUTIONS

GT DIAGNOSTICS

DEMENTIA DETECTION APPLICATIONS & DIAGNOSTIC SOLUTIONS

EXPERTS IN NEURODEGENERATIVE DISEASE RESEARCH

GT Diagnostics develops readily deployable e-platform tools that range from interactive well-being apps that can be used at home to comprehensive tools for expert use targeting the diagnosis and monitoring of dementia.

GT Diagnostics' tools are designed to be made available through various service providers including personal advice and support systems, residential and non-residential care, and specialised dementia centres.

About Us

Genting TauRx Diagnostic Centre Sdn Bhd and its wholly owned subsidiary GT Diagnostics (UK) Limited (jointly GT Diagnostics) was formed to enable basic research in dementia diagnosis to transition into clinical development.

GT Diagnostics is currently in the final development stage of four diagnostic and monitoring tools for dementia.

Vision & Mission

Driven by the values of our founding partners, we aim to change the diagnostic landscape and market in dementia. Our mission is to provide the missing tools for early diagnosis and monitoring of disease progression in dementia; tools that can be used in the comfort of one's home to tools that require administration by experts. These tools are designed with the aim to benefit millions who are worried about their cognitive health.

A Complete Partnership

Genting Berhad are embracing innovation and the adoption of new technology while TauRx Therapeutics are committed to the development of a treatment for dementia. As a result of their partnership, they have founded GT Diagnostics to develop intelligent tools to assist with early dementia detection.

GENTING
BERHAD

GT DIAGNOSTICS

GT DIAGNOSTICS

A TEAM WITH MORE THAN A CENTURY OF COMBINED EXPERIENCE

GT Diagnostics develops readily deployable e-platform tools that range from interactive well-being apps that can be used at home to comprehensive tools for expert use targeting the diagnosis and monitoring of dementia.

GT Diagnostics' tools are designed to be made available through various service providers including personal advice and support systems, residential and non-residential care, and specialised dementia

Team Leads

PROF BJOERN SCHELTER
CEO

- Over 100 scientific publications
- Almost 5000 citations

For more than 20 years, Professor Bjoern Schelter has led a scientific research team dedicated to finding novel data analysis techniques. For 7 years, he has focused on the development of novel diagnostic tools for the diagnosis of dementias.

LINDA SOMMERLADE
Head of Operations

With more than 15 years of experience in data analysis, QMS and project management in the Life Sciences, Dr Sommerlade leads the development of HiPAL, HiPAL Pro and SigNeXx.

KASIA LECH
QMS Lead

Kasia Lech with her outstanding attention to detail leads our QMS activities. This is done with a clear focus on meeting regulatory submission timelines. External validation of our efforts is provided by various consultants.

HELEN SHIELLS
Lead for PsyCoXx *(Maternity leave)*

Dr Shiells looks back to more than 8 years experience in data-based modelling and statistics in dementia research. She spearheads the development of PsyCoXx.

MILES WELSTEAD
### Psychologist/Lead for PsyCoXx *(Maternity cover)*

Miles Welstead has been involved in the development of Hipal, Hipal Pro, and PsyCoXx, specifically working to ensure that cognitive assessment elements of these tests are accurate and informative.

Get in touch

GT DIAGNOSTICS

Bringing Dementia Diagnostics into the 21st Century.

Genting TauRx Diagnostic Centre Sdn Bhd, a company established in Malaysia, and its wholly owned subsidiary GT Diagnostics (UK) Limited, was founded as a collaboration between Genting Berhad and TauRx Pharmaceuticals Ltd Group, with the vision to change the diagnostic landscape and market in dementia.

Sensitive to the early stages of dementia.

Robustly monitoring disease progression.

Objective imaging-based technology.

Providing comprehensive view of disease.

Global Context

ONE OF THE WORLD'S GREATEST UNMET MEDICAL NEEDS

EPIDEMIC

As the world's population ages, the prevalence of Alzheimer's Disease is predicted to reach epidemic proportions.

132 MILLION

50m people currently living with Alzheimer's Disease predicted to rise to 75m by 2030 and 132m by 2050.

IMPACT

Huge financial impact on public healthcare and devastating for patients, families and caregivers.

$1 TRILLION

Health care payments for people with Alzheimer's Disease forecast to increase from $290bn in 2019 to $1.1tr in 2050.

New Patient Journey

2 Initial appointment, waiting room: advanced diagnostic tools confirm.

1 First steps taken at home using engaging and interactive assessment tools.

3 Treatment prescribed, effect measured by accessible, ongoing monitoring tools.

OUR PRODUCTS

HiPAL
Memory Testing

HiPALPRO
Advanced Memory Testing

PsyCoXx
Cognitive Testing

SigNeXx
EEG Network Analysis

Current Patient Journey

1 Initial suspicion of cognitive impairment/AD.

2 Initial appointment, referral to specialist.

3 Wait period...

4 Specialist appointment, tests...

5 Cognitive assessment through expensive and non-mobile technologies.

6 Diagnosis of AD.

7 Specialist advice on possible (symptomatic) treatment.

8 Management of symptoms.

9 Outcome...

THE EXTENT OF THE PROBLEM...

3 people in 500* are currently diagnosed with dementia.

9 people in 500* have dementia but are undiagnosed.

90 people in 500* have changes in their brain that could lead to dementia.

* of the people aged over 45.

GT DIAGNOSTICS

DEMENTIA DETECTION APPLICATIONS & DIAGNOSTIC SOLUTIONS

GT Diagnostics develops readily deployable e-platform tools that range from interactive well-being apps that can be used at home to comprehensive tools for expert use targeting the diagnosis and monitoring of dementia. GT Diagnostics' tools are designed to be made available through various service providers including personal advice and support systems, residential and non-residential care, and specialised dementia centres.

HiPAL
Memory Testing

An engaging and interactive well-being app that permits those concerned about their cognitive health to monitor their status at home.

HiPALPRO
Advanced Memory Testing

A self-administered engaging and interactive tool running on a tablet, supporting clinicians in evaluating objective and subjective memory and mental processing speed.

PsyCoXx
Cognitive Testing

A specialised neuropsychological testing tool for clinicians to use in their assessment of patients with suspected or confirmed dementia, including Alzheimer's disease.

SigNeXx
EEG Network Analysis

A non-invasive, advanced EEG-based analysis tool, using standard EEG acquisition devices to provide an objective measure of brain connectivity.

Get in touch

www.gtdiag.com | contact@gtdiag.com | +44 (0)1224 440990

HiPAL
Memory Testing

A well-being app that permits those worried about their cognitive health to monitor their status at home.

Imagine you could regularly test your cognitive performance in the comfort of your home. Imagine subtle changes could be identified very early. Imagine the data collected over the years is not wasted but could be shared readily with experts who can not only help you but also have access to more advanced tools.

GT DIAGNOSTICS

HiPAL
Memory Testing

- **Engaging and interactive testing**
- **Traffic light system**
- **3 minutes per test**
- **Accurate cognitive health results**
- **Results history log**

HiPALPRO
Advanced Memory Testing

A self-administered engaging and interactive tool running on a tablet, HiPAL Pro supports clinicians with professionally evaluating objective and subjective memory and mental processing speed, and can be used in waiting rooms of primary care facilities or expert centres.

HiPAL Pro is GT Diagnostics' professional tool which is currently under development with the aim to be able to seamlessly integrate with HiPAL.

Through more comprehensive testing, HiPAL Pro is designed to provide an advanced output aimed at assisting in the diagnosis and monitoring of dementia, in particular, Alzheimer's disease.

With minimal set-up by the clinician, the application presents a self-administered psychometric test to the patient, examining aspects of cognition such as memory and executive function.

Individual patient results are presented as predicted scores for well-established standard questionnaire based assessments, allowing the clinician to evaluate their patient according to well-defined and characterised measures.

SPEED-ACCURACY TRADE-OFF

CONSCIOUS LEARNING

METACOGNITIVE JUDGEMENT

GT DIAGNOSTICS

# HiPALPRO

Advanced Memory Testing

- Engaging and interactive testing
- Professional tool
- Short tests supporting diagnosis
- Improves efficiency
- Accurate cognitive health results
- Integrates with other tools
- Enables monitoring over time

PsyCoXx
Cognitive Testing

A specialised neuropsychological testing tool for clinicians to use in their assessment of patients with suspected or confirmed dementia, including Alzheimer's disease.

PsyCoXx can be used flexibly to aid in diagnosis and to assess or monitor patients across multiple disease domains using a novel, proprietary algorithm.

PsyCoXx is administered using a computer and presents the clinician with questions tailored to individual patient ability. The test calculates patient scores and measures confidence in these scores, across the three different domains. The patient scores and confidence intervals are dynamically updated as the patient answers more questions, until a confidence threshold is met. Clinicians then have patient scores across the three disease-relevant domains, which can be used to aid in diagnosis or to monitor disease severity.

GT DIAGNOSTICS

PROFESSIONAL TOOL | PROVIDES FULL 3D VIEW OF A PATIENT | COMPUTER ADAPTIVE